 |
|
|
| |
Elafibranor treatment results in rapid reductions in biochemical markers and symptom burden in real-world practice: Interim results from the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis
|
| |
| |
EASL 2026 May 26-30 Barcelona
Jorn M. Schattenberg,1,2
|
| |
|
|
|
|
|
